Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma

Ayako Kawabata, Kawabata A, Nozomu Yanaihara, Yanaihara N, Chie Nagata, Nagata C, Misato Saito, Saito M, Noguchi D, Daito Noguchi, Masataka Takenaka, Takenaka M, Yasushi Iida, Iida Y, Takano H, Hirokuni Takano, Kyosuke Yamada, Yamada K, Masami Iwamoto, Iwamoto M, Kiyokawa T, Takako Kiyokawa, Aikou Okamoto, Okamoto A
Gynecologic oncology · 2017 · doi:10.1016/j.ygyno.2017.06.027 · PMID:28673661
other OA: green CC-BY-NC-ND-4.0
🔓 Open OA copy Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Substage classification and high interleukin-6 expression were associated with poor overall survival in patients with stage I ovarian clear cell carcinoma.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This paper examined the prognostic impact of interleukin-6 (IL-6) expression in stage I ovarian clear cell carcinoma, focusing on clinical-pathological associations. Using tumor expression data summarized in a high-level thesis/associated publication context, it identified IL-6 expression as a marker related to prognosis, with the analysis also framed around other features such as ARID1A expression. A key limitation explicitly relevant to interpreting prognostic biomarkers is that the dataset is confined to stage I disease and is limited by the retrospective/observational nature typical of correlative clinical-pathology studies. Relevance to endometriosis: this paper is centrally about ovarian clear cell carcinoma and IL-6 prognostic expression, and endometriosis is not explicitly discussed in the provided metadata, so it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: Ovarian clear cell carcinoma (OCCC) frequently presents at an early stage. In stage I OCCC, the prognosis differs according to substage. In particular, predictive biomarkers and new treatment strategies are needed for stage IC2/IC3 disease. We investigated tumor biology and prognostic factors for stage I OCCC from a clinicopathological perspective, including the expression of ARID1A and IL-6, which are considered critical for OCCC carcinogenesis. METHODS: A retrospective cohort study of 192 patients with stage I OCCC treated at a single institution was performed. We calculated overall survival (OS) with respect to 12 clinicopathological parameters that included the unique and diverse histological features of OCCC. RESULTS: The estimated 5-year OS rate in patients with all stage I OCCC was 88.9% during a median of 91months of follow-up. The multivariate analysis indicated that substage classification and IL-6 expression status were associated with poor OS (p=0.010 and p=0.027, respectively). Loss of ARID1A expression had no impact on survival; however, it was associated with substage (p=0.001), capsule rupture status (p=0.011), and ascites cytology (p=0.016). No clear association was found between ARID1A and IL-6 expressions. Histological findings, including the presence of endometriosis, adenofibroma, architectural pattern, and tumor cell type, showed no prognostic effects. CONCLUSIONS: Both substage classification and IL-6 expression status may be independent prognostic factors in stage I OCCC. Therefore, IL-6 molecular stratification may be crucial in optimizing therapeutic strategies for early stage OCCC to improve survival.
Full text 2,649 characters · extracted from oa-html · click to expand
WEKO3 アイテム Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma http://hdl.handle.net/10328/00019343 http://hdl.handle.net/10328/00019343fd6bc5f4-3b4a-416f-b54f-159de77998c3 | アイテムタイプ | 学位論文 / Thesis or Dissertation(1) | ||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| | 公開日 | 2022-11-15 | ||||||||||||| | タイトル | |||||||||||||| | タイトル | Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma | ||||||||||||| | 言語 | en | ||||||||||||| | 言語 | |||||||||||||| | 言語 | eng | ||||||||||||| | 資源タイプ | |||||||||||||| | 資源タイプ識別子 | http://purl.org/coar/resource_type/c_46ec | ||||||||||||| | 資源タイプ | thesis | ||||||||||||| | アクセス権 | |||||||||||||| | アクセス権 | metadata only access | ||||||||||||| | アクセス権URI | http://purl.org/coar/access_right/c_14cb | ||||||||||||| | 別タイトル | |||||||||||||| | その他のタイトル | I期卵巣明細胞癌における臨床病理学的検討―ARID1A, IL-6発現を中心に― | ||||||||||||| | 言語 | ja | ||||||||||||| | 著者 | 川畑, 絢子 × 川畑, 絢子 | ||||||||||||| | 著者所属 | |||||||||||||| | 値 | 産婦人科学 | ||||||||||||| | 指導教官 | |||||||||||||| | 値 | 岡本, 愛光 | ||||||||||||| | 国立情報学研究所 メタデータ主題語彙集（資源タイプ） | |||||||||||||| | 言語 | en | ||||||||||||| | 値 | Thesis or Dissertation | ||||||||||||| | 収録物識別子 | |||||||||||||| | 収録物識別子タイプ | PISSN | ||||||||||||| | 収録物識別子 | 0090-8258 | ||||||||||||| | 収録物識別子 | |||||||||||||| | 収録物識別子タイプ | EISSN | ||||||||||||| | 収録物識別子 | 1095-6859 | ||||||||||||| | 収録物識別子 | |||||||||||||| | 収録物識別子タイプ | NCID | ||||||||||||| | 収録物識別子 | AA00660708 | ||||||||||||| | 収録物識別子 | |||||||||||||| | 収録物識別子タイプ | NCID | ||||||||||||| | 収録物識別子 | AA11538364 | ||||||||||||| | 雑誌名 | Gynecologic Oncology 巻 146, 号 3, p. 609-614, 発行日 2017-09 | ||||||||||||| | 関連情報 | |||||||||||||| | 識別子タイプ | PMID | ||||||||||||| | 関連識別子 | 28673661 | ||||||||||||| | 関連情報 | |||||||||||||| | 関連タイプ | isVersionOf | ||||||||||||| | 識別子タイプ | DOI | ||||||||||||| | 関連識別子 | https://doi.org/10.1016/j.ygyno.2017.06.027 | ||||||||||||| | 異版である | |||||||||||||| | 関連タイプ | isVersionOf | ||||||||||||| | 識別子タイプ | URI | ||||||||||||| | 関連識別子 | https://doi.org/10.1016/j.ygyno.2017.06.027 | ||||||||||||| | 学位審査委員長 | |||||||||||||| | 値 | 衛藤 謙 | ||||||||||||| | 学位審査委員 | |||||||||||||| | 値 | 下田, 将之 | ||||||||||||| | 学位審査委員 | |||||||||||||| | 値 | 木村, 高弘 | ||||||||||||| | 学位授与番号 | |||||||||||||| | 学位授与番号 | 乙第3410号 | ||||||||||||| | 学位授与年月日 | |||||||||||||| | 学位授与年月日 | 2022-12-28 | ||||||||||||| | 学位名 | |||||||||||||| | 学位名 | 博士（医学） | ||||||||||||| | 言語 | ja | ||||||||||||| | 学位授与機関 | |||||||||||||| | 学位授与機関識別子Scheme | kakenhi | ||||||||||||| | 学位授与機関識別子 | 32651 | ||||||||||||| | 学位授与機関名 | 東京慈恵会医科大学 | ||||||||||||| | 言語 | ja |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Interleukin-6 Ovarian Neoplasms Ovarian Neoplasms Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adult Aged Aged, 80 and over Ascites Ascites Biomarkers, Tumor Biomarkers, Tumor DNA-Binding Proteins Female Humans Interleukin-6 Middle Aged Neoplasm Staging

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-07-30T06:25:42.655704+00:00
pubmed
last seen: 2026-05-13T22:20:19.560968+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: CC-BY-NC-ND-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine